Alexanderson-Rosas E, Meave-González A, Jordán-Ríos A, Berríos-Bárcenas E, Martínez-Aguilar M, Maury S, Magaña-Bailón E, Rodríguez-Ávila S, Valdivia C

Language: Spanish
References: 24
Page: 103-109
PDF size: 571.01 Kb.

ABSTRACT

Background: the cardiotoxic effects of antineoplastic treatments have been described for several years. The development of non-invasive cardiovascular imaging, and especially cardiac magnetic resonance, have permitted a better understanding of the physiopathology, and earlier diagnosis of these complications. The objective of this study was to evaluate intramyocardial delayed enhancement in Mexican population which received antineoplastic treatment (cisplatin + vinorelbine ± nimotuzumab) for cervico-uterine cancer. This is the first study to evaluate cardiotoxicity diagnosed by cardiac magnetic resonance in patients who take these drugs.
Material and methods: a prolective and prospective observational study in 46 patients with diagnosis of stage 4 cervical carcinoma, between 25 and 70 years of age, treated with first-line chemotherapy, without radiological evidence of metastasis, without prior cardiovascular comorbidity. Subjects underwent cardiac magnetic resonance before receiving chemotherapy and 6 months after.
Results: the patients’ average age was 49 ± 9.6 years. In the initial study, 34.8% of patients had delayed enhancement with insignificant increase (to 41.3%) in the studio at the end of the follow-up period. No significant changes were observed in hemodynamic parameters of the left ventricle following chemotherapy. Ventricular remodeling was observed in 17.4% and drop in left ventricular ejection fraction (of at least 10 percentage points) in 8.6%.
Conclusion: cancer patients present intramyocardial delayed enhancement from before antineoplastic treatment. Following administration of chemotherapy signs of ventricular remodeling can be observed in short-term follow-up.

REFERENCES

1. Schwartz R, Jain D, Storozynsky E. Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively. J Nucl Cardiol 2013;20:443- 64.

2. Ye E, Bickford C. Cardiovascular complications of cancer therapy. J Am Coll Cardiol 2009;53:2231-47.

3. Shakir D, Rasul K. Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management. J Clin Med Res 2009;1:8-12.

4. Lipshultz SE, Cochran TR, Franco VI, et al. Treatment-related cardiotoxicity in survivors of childhood cancer. Nat Rev Clin Oncol 2013;10:697-710.

5. Bovelli D, Plataniotis G, Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 2010:21;277- 82.

6. Lenihan D, Oliva S, Chow E, et al. Cardiac toxicity in cancer survivors. Cancer 2013;119:2131-42.

7. Hunt SA, Abraham WT, Chin MH, et al. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in adults. A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-e90.

8. Tocchetti CG, Ragone G, Coppola C, et al. Detection, monitoring and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. Eur J Heart Fail 2012;14:130-7.

9. Altena R, Perik PJ, van Veldhuisen DJ, et al. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009;10:391-399.

10. Murray LJ, Ramakrishnan S, O’Toole L, et al. Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery. Breast 2010;19:339-44.

11. Fallah-Rad N, Walker JR, Wassef A, et al. The utility of cardiac bio-markers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011;57:2263-70.

12. Zagrosek A, Abdel-Aty H, Boye P, et al. Cardiac magnetic resonance monitors reversible and irreversible myocardial injury in myocarditis. J Am Coll Cardiol Imaging 2009;2:131-8.

13. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR. Appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging. J Am Coll Cardiol 2006;48:1475-97.

14. Iles L, Pfluger H, Phrommintikul A, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T 1 mapping. J Am Coll Cardiol 2008;52:1574-80.

15. Fallah-Rad N, Lytwyn M, Fang T, et al. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson 2008;10:5.

16. Ho E, Brown A, Barrett P, et al. Subclinical anthracyclineand trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart 2010;96:701-7.

17. Wassmuth R, Lentszch S, Erdbruegger U, et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging—a pilot study. Am Heart J 2001;141:1007-13.

18. Lightfoot JC, D’Agostino RB Jr, Hamilton CA, et al. Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. Circ Cardiovasc Imaging 2010;3:550-8.

19. Jiji R, Kramer C, Salerno M. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. J Nucl Cardiol 2012;19:377-88.

20. Vasu S, Hundley WG. Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance 2013;15:66.

21. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72.

22. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215–21.

23. Liu CY, Liu YC, Wu C, et al. Evaluation of Age-Related Interstitial Myocardial Fibrosis With Cardiac Magnetic Resonance Contrast-Enhanced T1 Mapping. MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2013;62:1280–7.

24. Ylanen K, Poutanen T, Savikurki-Heikkla P, et al. Cardiac Magnetic Resonance Imaging in the Evaluation of the Late Effects of Anthracyclines Among Long-Term Survivors of Childhood Cancer. J Am Coll Cardiol 2013;61:1539–47.